Pharmacological characterization of dopamine-stimulated [35S]-Guanosine 5'-(γ-thiotriphosphate) ([35S]GTPγS) binding in rat striatal membranes

Biochemical Pharmacology

Volumn 57, Issue 2, 1999, Pages 155-162

  Rinken, Ago ^a   Finnman, Ulla Britt ^b   Fuxe, Kjell ^b  

^a UNIVERSITY OF TARTU   (Estonia)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

35S GTP S binding; Agonist binding; D2 subtype; G protein; Rat striatum, dopamine receptors

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; PERGOLIDE; QUINPIROLE; RECEPTOR SUBTYPE; REMOXIPRIDE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUANOSINE DIPHOSPHATE; LOGISTIC MODELS; MEMBRANES; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D2; STIMULATION, CHEMICAL; SULFUR RADIOISOTOPES;

EID: 0032950125     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00287-1     Document Type: Article

References (46)

1. Kebabian J.W., Calne D.B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
2. Sibley D.R., Monsma F.J. Molecular biology of dopamine receptors. Trends Pharmacol Sci. 13:1992;61-69.
3. Civelli O., Bunzow J.R., Grandy D.K. Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol. 33:1993;281-307.
4. Neer N.J., Heterotrimeric G. proteins Organizers of transmembrane signals . Cell. 80:1995;249-257.
5. Nürnberg B., Gudermann T., Schultz G. Receptors and G proteins as primary components of transmembrane signal transduction. 2. G proteins Structure and function . J Mol Med. 73:1995;123-132.
6. Haga T., Haga K. Interactions of muscarinic acetylcholine receptors (mAChRs) with G-proteins. Hulme E.C. Receptor-Effector Coupling. A Practical Approach. 1990;83-98 IRL Press, Oxford.
7. 2 muscarinic acetylcholine receptors with GTP-binding regulatory proteins in solution. J Biochem. 120:1996;193-200.
8. Onali P., Olianas M.C. Pharmacological and biochemical characterization of dopamine receptors mediating stimulation of a high affinity GTPase in rat striatum. Biochem Pharmacol. 36:1987;2839-2845.
9. Odagaki Y., Fuxe K. Functional coupling of dopamine D-2 and muscarinic cholinergic receptors to their respective G proteins assessed by agonist-induced activation of high-affinity GTPase activity in rat striatal membranes. Biochem Pharmacol. 50:1995;325-335.
10. Gierschik P., Bouillon T., Jakobs K.H. Receptor-stimulated hydrolysis of guanosine 5′-triphosphate in membrane preparations. Method Enzymol. 237:1994;13-26.
11. Wieland T., Jakobs K.H. Measurement of receptor-stimulated guanosine 5′-O-(γ-thio)triphosphate binding by G proteins. Method Enzymol. 237:1994;3-13.
12. Shiozaki K., Haga T. Effects of magnesium ion on the interaction of atrial muscarinic acetylcholine receptors and GTP-binding regulatory proteins. Biochemistry. 31:1992;10634-10642.
13. 35S]GTPγS binding. Br J Pharmacol. 121:1997;1203-1209.
14. 35S]GTPγS binding to membranes Determination of potencies and efficacies of ligands . J Pharmacol Exp Ther. 282:1997;676-684.
15. 1B receptor . Br J Pharmacol. 123:1998;51-62.
16. 4.4 receptors Actions of antiparkinsonian and antipsychotic agents . J Pharmacol Exp Ther. 282:1997;181-191.
17. 2long dopamine receptors expressed in recombinant cells. Br J Pharmacol. 118:1996;1544-1550.
18. 3 dopamine receptor. Neurosci Lett. 226:1997;91-94.
19. 4 receptor. J Neurochem. 68:1997;804-812.
20. 2 dopamine receptors in a reconstituted system . J Biol Chem. 265:1990;4507-4514.
21. Odagaki Y., Fuxe K. 5-HT1A, GABA(B), and pirenzepine-insensitive muscarinic receptors are functionally coupled to distinct pools of the same kind of G proteins in rat hippocampus. Brain Res. 689:1995;129-135.
22. 1A receptor-activated G-proteins in the rat brain. Brain Res Bull. 44:1997;39-45.
23. Friedman E., Butkerait P., Wang H.Y. Analysis of receptor-stimulated and basal guanine nucleotide binding to membrane G proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem. 214:1993;171-178.
24. S proteins. J Pharmacol Exp Ther. 273:1995;492-498.
25. Friedman E., Yadin E., Wang H.-Y. Effect of prenatal cocaine on dopamine receptor-G protein coupling in mesocortical regions of the rabbit brain. Neuroscience. 70:1996;739-747.
26. Peterson G.L. Determination of total protein. Method Enzymol. 91:1983;95-119.
27. Schild H.O. pA, a new scale for measurement of drug antagonism. Br J Pharmacol. 2:1947;189-206.
28. 4 receptors Antagonist studies . Br J Pharmacol. 109:1993;1120-1127.
29. 50) of an enzymatic reaction. Biochem Pharmacol. 22:1973;3099-3108.
30. Tota M.R., Kahler K.R., Schimerlik M.I. Reconstitution of the purified porcine atrial muscarinic acetylcholine receptor with purified porcine atrial inhibitory guanine mucleotide binding protein. Biochemistry. 26:1987;8175-8182.
31. Huff R.M., Axton J.M., Neer E.J. Physical and immunological characterization of a guanine nucleotide-binding protein purified from bovine cerebral cortex. J Biol Chem. 260:1985;10864-10871.
32. Motulsky H.J., Mahan L.C. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol. 25:1984;1-9.
33. Lazareno S., Birdsall N.J. Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Pharmacol. 109:1993;1110-1119.
34. 1 receptor pharmacology. ISI Atlas Sci Pharmacol. 2:1988;161-170.
35. Urwyler S. Affinity shifts induced by cations do not reliably predict the agonistic or antagonistic nature of ligands at brain. J Neurochem. 49:1987;1415-1420.
36. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
37. 2 receptor . Eur J Pharmacol Mol Pharmacol. 225:1992;331-337.
38. Seeman P., Van Tol H.H. Dopamine receptor pharmacology. Trends Pharmacol Sci. 15:1994;264-270.
39. 35S] thiotriphosphate) binding by cholinergic muscarinic receptors in membranes of rat olfactory bulb. J Neurochem. 67:1996;2549-2556.
40. Rinken A., Haga T. Solubilization and characterization of atrial muscarinic acetylcholine receptors in sucrose monolaurate. Arch Biochem Biophys. 301:1993;158-164.
41. Fong T.M. Mechanistic hypotheses for the activation of G-protein-coupled receptors. Cell Signal. 8:1996;217-224.
42. Kenakin T. Agonist-receptor efficacy. I Mechanism of efficacy and receptor promiscuity . Trends Pharmacol Sci. 16:1995;188-192.
43. Black J.W., Leff P., Shankley N.P., Wood J. An operational model of pharmacological agomism The effect of E/[A] curve shape on agonist dissociation constant estimation . Br J Pharmacol. 84:1985;561-571.
44. 2A receptors. Neurosci Lett. 239:1997;61-64.
45. Rinken A., Harro J., Engström L., Oreland L. Role of fluidity of membranes on the guanyl nucleotide-dependent binding of cholecystokinin 8-S to rat brain cortical membranes. Biochem Pharmacol. 55:1998;423-431.
46. 35S]guanosine-5′-O-(3-thio)triphosphate binding Agonist potencies and the influence of sodium chloride on intrinsic activity . Mol Pharmacol. 51:1997;1060-1069.